Suppliers / FDC

FDC

India 3 duplicate records merged Updated 9 July 2026

FDC is an API and finished-dose manufacturer based in India. It holds 15 active US drug master files and 48 valid CEPs across a filed portfolio of 20 molecules. Its filings concentrate with MCAZ (ZW), EFDA (ET) and TMDA (TZ). Its GMP standing is certified by MHRA (UK), EMA and FDA (GH), among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 24 March 2023 as NAI. Customs aggregates show $15.5M of exports covering 673 molecules to 64 destinations in 2025.

15
active US DMFs
48
valid CEPs
9
registered plants 4 with an FDA FEI number
161
filings across 16 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
4 of 4 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 24 March 2023 NAI US FDA
  • 12 February 2023 NAI US FDA
  • 16 August 2018 VAI US FDA
  • 4 May 2018 NAI US FDA
  • 1 July 2016 VAI US FDA
  • 11 February 2016 NAI US FDA
  • 5 March 2015 VAI US FDA
  • 6 May 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Aurangabad, United Arab Emirates Not on file
Chhatrapati Sambhajinagar, India 3003204330
VERNA SALCETTE, India Not on file
AURANGABAD, India Not on file
VERNA, India Not on file
Roha, India 3002806958

3 further sites are on record.

What they file, and where

Molecule Regulators Docs
Miconazole EDQM, SFDA (Saudi Arabia), US FDA 8
Flurbiprofen EDQM, US FDA 7
Albuterol EDQM, SFDA (Saudi Arabia), US FDA 5
Cinnarizine EDQM, SFDA (Saudi Arabia), US FDA 5
Timolol EDQM, SFDA (Saudi Arabia), US FDA 5
Brimonidine EDQM, US FDA 4
Bromhexine EDQM, SFDA (Saudi Arabia) 4
Dorzolamide EDQM, US FDA 4
Econazole EDQM, US FDA 4
Latanoprost EDQM, US FDA 4
Show all 20 molecules on file
Betaxolol EDQM 3
Fluconazole EDQM 3
Glycopyrronium EDQM 3
Rupatadine EDQM 3
Arformoterol US FDA 1
Bimatoprost US FDA 1
Brinzolamide US FDA 1
Nepafenac US FDA 1
Olopatadine US FDA 1
Semaglutide US FDA 1

Also appears on these molecule pages

Show 14 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MCAZ (ZW) 30 None
EFDA (ET) 26 None
TMDA (TZ) 24 None
MHRA (UK) 19 2
EMA 17 2
US FDA 10 None
FDA (GH) None 1
ZAMRA (ZM) None 1
NAFDAC (NG) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $7.0M 62
2025 Not reported $15.5M 64
2024 Not reported $13.6M 66
2023 Not reported $78.7M 58

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. FDC comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 24 March 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts